ChiCTR-COC-17012522 版本V1.0 版本创建时间2022/06/09 09:59:41 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-COC-17012522 

最近更新日期:

Date of Last Refreshed on:

2017-08-31 23:54:49 

注册时间:

Date of Registration:

2017-08-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

跨中缅边境疟疾感染危险因素研究

Public title:

Research of risk factors for malaria infection along cross China-Myanmar border

注册题目简写:

中缅边境疟疾感染危险因素

English Acronym:

Risk factors for malaria infection, CN-MMR

研究课题的正式科学名称:

跨中缅边境疟疾感染危险因素和间日疟根治难题研究

Scientific title:

Research of risk factors for malaria infection and radical treatment regimen along cross China-Myanmar border

研究课题代号(代码):

Study subject ID:

81560543

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

许建卫 

研究负责人:

刘慧 

Applicant:

Jianwei XU 

Study leader:

Hui LIU 

申请注册联系人电话:

Applicant telephone:

+86 18987921137

研究负责人电话:

Study leader's
telephone:

+86 15308796079

申请注册联系人传真 :

Applicant Fax:

+86 0879 2122153

研究负责人传真:

Study leader's fax:

+86 0879 2122153

申请注册联系人电子邮件:

Applicant E-mail:

xjw426@163.com

研究负责人电子邮件:

Study leader's E-mail:

liubible@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

http://www.yipd.org

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

http://www.yipd.org

申请注册联系人通讯地址:

云南省普洱市思茅区西园路6号

研究负责人通讯地址:

云南省普洱市思茅区西园路6号

Applicant address:

6 Xiyuan Road, Simao District, Puer, Yunnan, China

Study leader's address:

6 Xiyuan Road, Simao District, Puer, Yunnan, China

申请注册联系人邮政编码:

Applicant postcode:

665000

研究负责人邮政编码:

Study leader's postcode:

665000

申请人所在单位:

云南省寄生虫病防治所

Applicant's institution:

Yunnan Institute of Parasitic Diseases

研究负责人所在单位:

云南省寄生虫病防治所

Affiliation of the Leader:

Yunnan Institute of Parasitic Diseases

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2015-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

云南省寄生虫病防治所医学伦理委员

Name of the ethic committee:

The Medical Ethics Committees of the Yunnan Institute of Parasitic Diseases, China

伦理委员会批准日期:

Date of approved by ethic committee:

2015-03-12 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

云南省寄生虫病防治所

Primary sponsor:

Yunnan Institute of Parasitic Diseases

研究实施负责(组长)单位地址:

云南省普洱市思茅区西园路6号

Primary sponsor's address:

6 Xiyuan Road, Simao District, Puer, Yunnan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

缅甸

省(直辖市):

克钦第二特区

市(区县):

拉咱市

Country:

Myanmar

Province:

Kachin Special Region 2

City:

Laza City

单位(医院):

拉咱市医院

具体地址:

拉咱市沿河路166号

Institution
hospital:

Laza City Hospital

Address:

166 Yanhe Road, Laza City

经费或物资来源:

国家自然科学基金委员会

Source(s) of funding:

National Nature Science Foundation of China

研究疾病:

疟疾  

Target disease:

malaria

研究疾病代码:

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

研究清楚中国消除疟疾阶段跨中缅边境地区的疟疾流行规律和疟疾感染危险因素,同时鉴定出疟疾流行的热点和热点人群,为有针对性地制定有效疟疾消除及其巩固维持消除成果的措施,提供科学依据和技术支撑。  

Objectives of Study:

To identify risk factors for malaria infection on the China-Myanmar border, to find epidemiological characteristics of malaria cross China-Myanmar border, hotspots and hot populations through using case-control technology, providing scientific evidences and technical support for measure developments of malaria elimination and maintaining the achievement of the elimination.

药物成份或治疗方案详述:

病例对照研究纳入人数比(病例数:对照数)为1:2;为排除年龄、性别和健康状况等混杂因素的影响,以性别相同,年龄(+/-5岁)和健康状况相似配对。对每个病例和对照进行问卷调查,收集有关疟疾感染危险因素的数据。 

Description for medicine or protocol of treatment in detail:

Case-control ratio 1:2. In order to exclude confounding factors, controls were matched by sex, age (± 5 years), sex and health status. A questionaire will be administrated to collect data on risk factors of malaria infections. 

纳入标准:

病例为医疗机构发热病人疟原虫镜检阳性者,对照为来自相同机构就医的非疟疾病人(疟原虫镜检阴性)。获得知情同意者均可以纳入。

Inclusion criteria

The case patients are malaria patients confirmed by microscopy, the control patients are malaria parasite free by microscopy. All those that informed consent were obtained can be included.

排除标准:

病例组PCR实验阴性和对照组PCR阳性者,数据分析时从研究对象中踢出。

Exclusion criteria:

Those whose results of PCR test for case patients is negative, and for control patients is positive, will excluded from dada analysis.

研究实施时间:

Study execute time:

From 2016-01-01 00:00:00 To 2019-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-10-01 00:00:00 To 2018-12-31 00:00:00

干预措施:

Interventions:

组别:

疟疾病例组

样本量:

162

Group:

Group of malaria cases

Sample size:

干预措施:

问卷调查

干预措施代码:

Intervention:

Questionnaire survey

Intervention code:

组别:

对照组

样本量:

324

Group:

Group of control

Sample size:

干预措施:

问卷调查

干预措施代码:

Intervention:

questionnaire survey

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

缅甸

省(直辖市):

克钦第二特区 

市(区县):

拉咱市 

Country:

Myanmar

Province:

Kachin Special Region 2

City:

Laza City

单位(医院):

拉咱市医院 

单位级别:

二级 

Institution
hospital:

Laza City Hospital

Level of the institution:

level 2

测量指标:

Outcomes:

指标中文名:

潜在危险因素的比值比

指标类型:

主要指标

Outcome:

Odds ratio of potential risk factors

Type:

Primary indicator

测量时间点:

测量方法:

问卷访谈

Measure time point of outcome:

Measure method:

Questionnaire interview

指标中文名:

潜在危险因素发生百分比

指标类型:

次要指标

Outcome:

Percentage of potential risk factors

Type:

Secondary indicator

测量时间点:

测量方法:

问卷访谈

Measure time point of outcome:

Measure method:

Questionnaire interview

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood samples

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 1 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

非随机

Randomization Procedure (please state who generates the random number sequence and by what method):

non Randomization

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

采用网络平台。网址:http://www.yipd.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Web-bassed public database. Website:http://www.yipd.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

问卷调查收集疟疾感染危险因素

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use Questionaire-based interview to collect risk factors of malaria infections

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-08-31 23:54:49